Nanovibronix (NASDAQ:FEED) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Nanovibronix (NASDAQ:FEED) to a hold rating in a report published on Saturday.

Separately, Weiss Ratings started coverage on Nanovibronix in a research note on Tuesday, January 27th. They set a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Nanovibronix Trading Up 1.5%

Nanovibronix stock opened at $2.75 on Friday. Nanovibronix has a 12 month low of $0.99 and a 12 month high of $162.50. The company has a market capitalization of $3.00 million, a P/E ratio of -0.07 and a beta of 2.21.

Insider Activity

In related news, major shareholder Christian Michael Glibert purchased 240,000 shares of the business’s stock in a transaction dated Wednesday, January 14th. The stock was purchased at an average cost of $2.67 per share, with a total value of $640,800.00. Following the completion of the acquisition, the insider directly owned 240,000 shares of the company’s stock, valued at approximately $640,800. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 1.40% of the stock is currently owned by corporate insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.